Raymond James: 'PROF meeting its FY26 revenue guidance is very much achievable'

October 8, 2026 6:52 AM

Raymond James analyst Michael Freeman reiterated a Strong Buy rating and $11.00 price target on Profound Medical Corp. (NASDAQ: PROF).The ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found